Top Page
Aroa Biosurgery Ltd
(Sydney:ARX)
Aroa Biosurgery Ltd (ARX) vs. iShares MSCI Australia ETF (EWA)
Aroa Biosurgery Ltd Business Overview & Revenue Model
Aroa Biosurgery Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 82.36M | 76.97M | 63.36M | 59.31M | 36.88M | 20.51M |
| Gross Profit | 70.39M | 65.99M | 54.10M | 50.06M | 28.17M | 14.25M |
| EBITDA | 5.06M | 2.65M | -6.78M | 683.92K | -3.75M | -7.05M |
| Net Income | -1.66M | -3.47M | -9.75M | -370.68K | -7.79M | -17.63M |
Balance Sheet | ||||||
| Total Assets | 95.27M | 98.94M | 101.88M | 109.07M | 104.71M | 73.12M |
| Cash, Cash Equivalents and Short-Term Investments | 20.71M | 20.13M | 27.73M | 43.00M | 53.35M | 33.93M |
| Total Debt | 6.14M | 5.83M | 6.82M | 6.65M | 5.46M | 14.90M |
| Total Liabilities | 14.34M | 14.35M | 14.79M | 13.69M | 11.30M | 19.43M |
| Stockholders Equity | 80.93M | 84.59M | 87.08M | 95.38M | 93.40M | 53.69M |
Cash Flow | ||||||
| Free Cash Flow | 4.60M | -5.69M | -10.00M | -10.66M | -15.39M | -6.05M |
| Operating Cash Flow | 5.73M | -2.33M | -6.76M | -3.53M | -10.86M | -4.68M |
| Investing Cash Flow | -10.79M | 273.54K | 9.31M | 6.79M | -32.41M | -19.74M |
| Financing Cash Flow | -1.83M | -1.34M | -948.41K | -471.78K | 34.98M | 34.06M |
Aroa Biosurgery Ltd Technical Analysis
Aroa Biosurgery Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$17.00B | 44.89 | 20.11% | 1.64% | 4.32% | 9.24% | |
56 Neutral | AU$234.92M | -141.67 | -2.01% | ― | 16.93% | 76.47% | |
54 Neutral | AU$670.12M | 50.79 | 16.49% | ― | 23.31% | 151.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$106.69M | -7.95 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$168.22M | -15.78 | -70.55% | ― | ― | -257.32% | |
44 Neutral | AU$1.93B | -47.67 | -44.49% | ― | 55.91% | 22.60% |
Aroa Biosurgery Ltd Corporate Events
Aroa Biosurgery Limited has applied for quotation on the ASX of 442,961 new fully paid ordinary shares issued on 29 January 2026 under an employee incentive scheme. The additional securities, to trade under the company’s existing ARX ticker, modestly increase the company’s free float and reflect the ongoing use of equity-based remuneration to retain and incentivise staff, with limited immediate impact on capital structure but signalling continued commitment to employee alignment with shareholder interests.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery has issued a February 2026 business update presentation aimed at investors, outlining general company information and educational material on its regenerative wound care technologies. The document emphasises that it is not a prospectus or securities offering, warns that any performance discussion includes inherently uncertain forward‑looking statements, and reiterates that product availability varies by region and results may differ between patients, framing the update as informational rather than promotional or advisory for investment decisions.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery says its Symphony wound-care product is well placed to benefit from new US Medicare rules that set a single outpatient reimbursement rate of US$127.14 per square centimetre for skin substitutes, a move the company expects will squeeze out higher-priced rivals and support Symphony’s uptake in hospital outpatient departments where it already has inpatient relationships. The company also highlighted new clinical data from its MASTRR registry showing that Myriad achieves rapid vascularised tissue coverage in complex trauma cases with low complication and application rates compared with competing bioscaffolds, reinforcing its potential to lower total care costs, and reaffirmed FY26 guidance with revenue expected near the top of its NZ$92–100 million range and normalised EBITDA of NZ$5–8 million, underpinned by strong sales momentum and a favourable US reimbursement backdrop.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited will host an investor webinar on 3 February, led by CEO Brian Ward and CFO James Agnew, to discuss a pre-market business update, including progress on Symphony™ and developments in US Medicare reimbursement, as well as newly published clinical data from the ongoing MASTRR study. The event signals the company’s efforts to deepen investor engagement and provide greater transparency around key growth drivers and clinical validation, with potential implications for its reimbursement outlook, product adoption and positioning in the US soft-tissue regeneration market.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery announced new interim data from its large, ongoing MASTRR registry showing that its Myriad Matrix and Myriad Morcells ovine-ECM bioscaffolds delivered effective and economical treatment of complex trauma and acute care surgery wounds. In 49 patients with 61 challenging, often contaminated defects treated across four US Level I trauma centres, wounds achieved full vascularised tissue coverage in a median of 22.5 days, typically after a single application and with no device-related complications, while cost comparisons against other bioscaffolds indicated Myriad is cheaper per centimetre with equivalent or superior key outcomes. Management and participating surgeons said the findings validate Myriad as a cost‑effective option that can lower total hospital care costs, reinforcing Aroa’s evidence base—now exceeding 116 peer‑reviewed studies—and highlighting a US trauma surgery market opportunity of roughly US$450 million that the company views as a strategic growth focus.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited, a medtech firm specialising in biosurgical and regenerative tissue products for surgical and wound care applications, is listed on the Australian Securities Exchange under the code ARX. The company has announced the cessation of 6,753 ARXAAK options, which lapsed on 19 October 2025 after conditions attached to the rights were not satisfied, resulting in a small reduction of potential dilutive securities on issue but no change to the existing ordinary share capital.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery has welcomed a decision by the US Centers for Medicare & Medicaid Services that ensures its Symphony wound-care products will remain available for outpatient treatment of diabetic foot ulcers and venous leg ulcers under Medicare at least through the end of 2026. CMS has introduced a three-tier classification for skin substitute products—covered, discretionary and non-covered—with Symphony placed in the discretionary category, allowing Medicare Administrative Contractors to reimburse it on a case-by-case basis while additional clinical data are gathered. Aroa has already completed a randomized controlled trial of Symphony, expects publication in 2026, and intends to submit the findings to Medicare contractors ahead of a year-end 2026 review that will underpin future coverage decisions, a process the company views as validating its clinical strategy and supporting continued access for US patients and clinicians.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd released its half-year results for 2026, highlighting its commitment to advancing regenerative healing technologies. The company continues to focus on enhancing its market position by developing innovative medical products, although specific financial details and impacts on stakeholders were not disclosed in the release.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited reported a 14% increase in total revenue for the first half of FY26, reaching NZ$44.9 million, with significant growth in its Myriad product line. The company achieved a normalized EBITDA profit of NZ$1.8 million, a significant improvement from a loss in the previous year, and ended the period with a positive net cash flow. Aroa also received relief from quarterly reporting requirements by the ASX, indicating a stable financial position and operational efficiency. The company reaffirmed its FY26 guidance, projecting continued revenue growth and improved EBITDA, signaling a positive outlook for stakeholders.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd reported a significant improvement in its financial performance for the six months ending 30 September 2025. The company achieved a 14% increase in product sales and a 259% rise in project fees, contributing to a 64% reduction in loss before tax from ordinary activities. This financial progress underscores Aroa’s strengthened market position and operational efficiency, which could positively impact stakeholders and enhance its competitive edge in the medical technology industry.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Ltd announced the issuance of unquoted equity securities, including 519,444 restricted stock units and 888,888 performance rights, as part of an employee incentive scheme. This move is likely aimed at enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and market positioning positively.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
Aroa Biosurgery Limited is hosting an investor event on November 25, 2025, to discuss its H1 FY26 financial results and commercial outlook. The event will feature presentations from Aroa’s leadership, commercial partner TelaBio, and surgeons discussing clinical outcomes using Aroa’s Myriad™ product. This gathering aims to provide investors with insights into Aroa’s product innovation, clinical efficacy, and growth trajectory, potentially influencing stakeholder perspectives and the company’s market positioning.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.